SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

 

Date of Report (Date of earliest event reported):  December 5, 2003

 

Vertex Pharmaceuticals Incorporated

(Exact name of registrant as specified in its charter)

 

MASSACHUSETTS

 

000-19319

 

04-3039129

(state or other jurisdiction
of incorporation)

 

(Commission File Number)

 

(IRS Employer
Identification No.

 

130 WAVERLY STREET
CAMBRIDGE, MA 02139

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (617) 444-6100

 

 

 

ITEM 5.   OTHER EVENTS.

 

On December 5, 2003, Joshua S. Boger, the Company’s Chairman and CEO, entered into a plan with Goldman, Sachs & Co., pursuant to which Goldman will undertake to sell, subject to a limit order, an aggregate of 370,000 shares of the Company’s stock issuable upon exercise of options held by Dr. Boger.  Sales under the plan are to begin no earlier than 90 days after adoption of the plan, and will take place at specified intervals between March 16, 2004 and March 15, 2005.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

VERTEX PHARMACEUTICALS INCORPORATED
(Registrant)

 

 

 

 

 

 

Date:  December 5, 2003

 

/s/ Ian F. Smith

 

 

 

Ian F. Smith

 

 

Senior Vice President and Chief Financial Officer

 

2